Effect of a Single High Loading Dose of Rosuvastatin on Percutaneous Coronary Intervention for Acute Coronary Syndromes. (July 2013)

• Record Type: Journal Article
• Authors: Wang, Zhengzhong; Dai, Hongyan; Xing, Mingqing; Yu, Zhongxiang; Lin, Xianru; Wang, Shoudong; Zhang, Junyi; Hou, Fangjie; Ma, Ying; Ren, Yongqiang; Tan, Kai; Wang, Yanping; Ge, Zhiming
• Is Part Of: Journal of cardiovascular pharmacology and therapeutics. Volume 18:Number 4(2013)
• Page Start: 327
• Page End: 333
• Publication Date: 2013-07
• Subjects: rosuvastatin -- percutaneous coronary intervention -- non-ST segment elevation acute coronary syndrome -- high-sensitivity C-reactive protein -- interleukin 6 -- monocyte chemotactic protein 1; Cardiovascular pharmacology -- Periodicals; Cardiovascular system -- Diseases -- Treatment -- Periodicals; 616
• DOI: 10.1177/1074248412474346
• Languages: English
• ISSNs: 1074-2484

Abstract

Objectives: A high loading dose of atorvastatin has been confirmed to reduce postprocedural events in patients undergoing percutaneous coronary intervention (PCI). In this study, we sought to investigate the protective effects of rosuvastatin in patients with acute coronary syndromes (ACS) undergoing PCI and to determine the effect of rosuvastatin pretreatment on the postprocedural levels of high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and monocyte chemotactic protein 1 (MCP-1). Methods: A total of 125 patients with non-ST-segment elevation ACS were randomized to pretreatment with rosuvastatin (20 mg 2-4 hours before PCI [n = 62]) or placebo (n = 63). All the patients received subsequent long-term rosuvastatin treatment (10 mg/d). The main end point of the trial was the 30-day incidence of major adverse cardiac events (death, myocardial infarction, or unplanned revascularization). Plasma levels of hs-CRP, IL-6, and MCP-1 were detected before PCI and 6 hours, 24 hours, and 3 days after PCI. Results: The primary end point occurred in 8.1% of the patients in the rosuvastatin arm and 22.2% in the placebo arm ( P < .01); this difference was entirely attributed to a reduced incidence of myocardial infarction (8.1% vs 22.2%; P < .01). The postprocedural elevation in creatine kinase-MB and troponin I was also significantly lower in the rosuvastatin group at 6 hours, 24 hours, and 3 days. Plasma levels of hs-CRP, IL-6, and MCP-1 increased significantly after PCI in both the rosuvastatin and control groups; however, the postprocedural elevations in hs-CRP and IL-6 levels were significantly lower in the rosuvastatin group than the control group. Conclusions: A single, high dose (20 mg) of rosuvastatin prior to PCI reduces postprocedural myocardial injury in patients with ACS, with a concomitant attenuation of the postprocedural increase in hs-CRP and IL-6 levels.